The efficacy of gene therapy against brain tumors will depend upon delivery of viral vector throughout tumor and specific cytotoxicity toward both infected and non-infected tumor cells. Previously this project has focused on delivery, assessing interstitial infusion and transvascular delivery of particles by osmotic opening of the blood-brain barrier (BBB). While delivery remains our major focus, the current proposal will also move to a broader examination of virus and particle uptake and efflux. In addition to recombinant adenovirus vectors, as a model for virus particles we will use viral-sized iron oxide nanoparticles, Combidex and Code7228, because they allow direct comparison of magnetic resonance (MR) imaging with histology and ultrastructure.
In Aim 1 we will assess influx and uptake of virus and iron particles into rat brain and intracerebral tumor, and investigate the effect of tumor size, permeability and prior irradiation. Since radiation may increase virus distribution and/or transgene expression, we will test a novel approach combining tumor-specific radioimmunotherapy with virus delivery.
This aim will also evaluate iron particle influx in a rat stroke model, and characterize phagocytic and/or astrocytic reactive cells responsible for iron particle trapping.
Aim 2 will evaluate virus and iron particle efflux from the brain, using mR and histology to delineate efflux pathways.
In Aim 3, we will investigate the potential for gene therapy with Herstatin, a secreted protein which inhibits the epidermal growth factor receptor (EGFR). We will compare intratumor vs. transvascular delivery of protein and a Hestatin adenovirus construct, both in the LX-1 lung cancer metastasis model, as well as in glioma and breast metastasis models. We hypothesize that because Herstatin is secreted and has high activity against EGFR overexpressing cells, it will provide bystander efficacy even when a small proportion of tumor is infected. Finally, Aim 4 will be an expanded clinical protocol of rion particle imaging and localization, to assess BBB and blood-tumor barrier permeability and Combidex uptake in adult and pediatric brain tumors, and in CNS inflammatory lesions. We will also evaluate tumor vascularity using MR angiography with Code7228, a new formulation which allows bolus administration and dynamic MRA superior to Gd. Our hypothesis is that tumor imaging with the iron oxide particle agents requires both a leaky BBB and trapping by uptake into reactive cells. We anticipate that these studies will not only be useful in designing clinical trials of brain tumor gene therapy, but also in providing a new means to image CNS tumors, neurological lesions and even gene therapy approaches which evoke a cellular reaction.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Fountain, Jane W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
Schools of Medicine
United States
Zip Code
Li, Xin; Varallyay, Csanad G; Gahramanov, Seymur et al. (2017) Pseudo-extravasation rate constant of dynamic susceptibility contrast-MRI determined from pharmacokinetic first principles. NMR Biomed 30:
Guillaume, Daniel J; Doolittle, Nancy D; Gahramanov, Seymur et al. (2010) Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery 66:48-58; discussion 58
Li, Xin; Rooney, William D; Várallyay, Csanád G et al. (2010) Dynamic-contrast-enhanced-MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. J Magn Reson 206:190-9
Thompson, Eric M; Dosa, Edit; Kraemer, Dale F et al. (2010) Treatment with bevacizumab plus carboplatin for recurrent malignant glioma. Neurosurgery 67:87-93
Angelov, Lilyana; Doolittle, Nancy D; Kraemer, Dale F et al. (2009) Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27:3503-9
Neuwelt, Edward A; Hamilton, Bronwyn E; Varallyay, Csanad G et al. (2009) Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 75:465-74
Jahnke, Kristoph; Muldoon, Leslie L; Varallyay, Csanad G et al. (2009) Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol 11:142-50
Doolittle, N D; Muldoon, L L; Brummett, R E et al. (2001) Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500
Doolittle, N D; Miner, M E; Hall, W A et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637-47